Poxel Announces Third Quarter 2026 Financial Results

Poxel reported a significant increase in its financial performance for the third quarter of 2026. The consolidated net sales of TWYMEEG® in Japan reached JPY 2.9 billion (€16.3 million), marking a 29% rise compared to the same period in 2025. For the first nine months of 2026, net sales increased by 32%, totaling JPY 8.1 billion (€44.5 million).

During Sumitomo Pharma's fiscal year 2026, Poxel's royalties increased from 8% to 10% after net sales of TWYMEEG® exceeded JPY 5 billion. As a result, Poxel recorded positive net royalties for the first time. Poxel's revenue for the third quarter was €1,951k, including a retroactive adjustment of €322k.

Sumitomo Pharma projects that TWYMEEG® sales will exceed JPY 10 billion for fiscal year 2026. If achieved, Poxel would receive a bonus of JPY 1 billion (€5.6 million) and the royalty rate would rise to 12%.